

Temporary benefits added to the *Alberta Drug Benefit List (ADBL)*

Due to the unavailability of the following products, GLN-Olmesartan 40 mg Tablet (DIN 02469820) manufactured by Glenmark Pharmaceuticals Canada Inc., will be considered as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

DIN	Product Description	Manufacturer
02442205	Act Olmesartan 40 mg Tablet	Actavis Pharma Company
02453460	Apo-Olmesartan 40 mg Tablet	Apotex Inc.
02443872	Auro-Olmesartan 40 mg Tablet	Auro Pharma Inc.
02461668	Jamp-Olmesartan 40 mg Tablet	Jamp Pharma Corporation
02461315	pms-Olmesartan 40 mg Tablet	Pharmascience Inc.
02443422	Sandoz Olmesartan 40 mg Tablet	Sandoz Canada Inc.
02318679	Olmetec 40 mg Tablet	Merck Canada Inc.

As of **February 6, 2020**, all claims for GLN-Olmesartan 40 mg Tablet (DIN 02469820) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at <https://www.ab.bluecross.ca/providers/pharmacy-home.php>

If this situation continues to be a long-term matter then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health for addition to the *ADBL* in order to remain as a benefit.

Due to the unavailability of Ultravate 0.05% Topical Cream (DIN 01962701), manufactured by Bausch Health, Ultravate 0.05% Topical Ointment (DIN 01962728), manufactured by Bausch Health, will be considered as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

As of **February 12, 2020**, all claims for Ultravate 0.05% Topical Ointment (DIN 01962728) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at <https://www.ab.bluecross.ca/providers/pharmacy-home.html>.

If this situation continues to be a long-term matter then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health for addition to the *ADBL* to remain as a benefit.

... continued from previous page

Due to the unavailability of Maxidex 0.1% Ophthalmic Suspension (DIN 00042560), manufactured by Novartis Pharmaceuticals Canada Inc., Dexamethasone 0.1% Ophthalmic Solution (DIN 02023865), manufactured by Pharma Stulln Inc., will be considered as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

As of **February 13, 2020**, all claims for Dexamethasone 0.1% Ophthalmic Solution (DIN 02023865) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at <https://www.ab.bluecross.ca/providers/pharmacy-home.html>.

If this situation continues to be a long-term matter then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health for addition to the *ADBL* to remain as a benefit.

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free)

FAX 780-498-8406 (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefits and supplemental claiming information to assist with the submission of your direct bill drug claims. **Visit** [ab.bluecross.ca/providers/pharmacy-home.php](https://www.ab.bluecross.ca/providers/pharmacy-home.php)



**The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. *† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.840 2020/02

